19023-94-0

Basic information

• Product Name: Cbz-N-Methylethylenediamine
• Synonyms: Cbz-N-Methylethylenediamine;benzyl 2-aminoethyl(methyl)carbamate;N-Benzyloxycarbonyl-N-methylethylenediamine;REF DUPL: N-Benzyloxycarbonyl-N-methylethylenediamine;benzyl 2-aminoethyl(methyl)carbamate HCl;N-(2-Aminoethyl)-N-methylcarbamic acid phenylmethyl ester;N-CBZ-N-METHYLETHYLENEDIAMINE
• CAS NO: 19023-94-0
• Molecular Formula: C₁₁H₁₆N₂O₂
• Molecular Weight: 208.25694
• Mol File: 19023-94-0.mol
• Article Data: 6

Chemical Properties

• Boiling Point: 327.6 °C at 760 mmHg
• Flash Point: 151.9 °C
• Appearance: /
• Density: 1.118
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.52
• CAS DataBase Reference: Cbz-N-Methylethylenediamine(CAS DataBase Reference)
• NIST Chemistry Reference: Cbz-N-Methylethylenediamine(19023-94-0)
• EPA Substance Registry System: Cbz-N-Methylethylenediamine(19023-94-0)

Safety Data

• Hazardous Substances Data: 19023-94-0(Hazardous Substances Data)

Usage

General Description

Cbz-N-Methylethylenediamine, also known as CbzNN-C6H10NH2, is an organic compound with the formula C11H17N3O2. It is a derivative of ethylenediamine and is used as a building block in the synthesis of pharmaceuticals and agrochemicals. Cbz-N-Methylethylenediamine is a versatile intermediate that can be further modified to create a variety of functional groups, making it valuable in the production of complex organic molecules. Its applications include the production of antifungal agents, antiviral drugs, and other biologically active compounds. The compound is typically handled and stored in a dry, well-ventilated area away from incompatible materials and sources of ignition.

InChI:InChI=1/C11H16N2O2/c1-12-7-8-13-11(14)15-9-10-5-3-2-4-6-10/h2-6,12H,7-9H2,1H3,(H,13,14)

Upstream product

• 40052-13-9 mono-tert-butyl malonate 
• 1221593-52-7 methyl-[2-(2,2,2-trifluoro-acetylamino)-ethyl]carbamic acid benzyl ester 
• 75315-63-8 N-(benzyloxycarbonyl)succinimide 
• 501-53-1 benzyl chloroformate 
• 109-81-9 N-methyl-ethane-1,2-diamine 
• 56221-05-7 N-Benzyliden-N'-methylethylendiamin 

Downstream Products

• 959154-70-2 C₃₂H₅₂N₆O₉ 
• 1048360-18-4 {(S)-4-({amino-[(E)-2,2,4,6,7-pentamethyl-2,3-dihydro-benzofuran-5-sulfonylimino]-methyl}-amino)-1-[2-(benzyloxycarbonyl-methyl-amino)-ethyl carbamoyl]-butyl}-carbamic acid tert-butyl ester 
• 1221593-56-1 {(S)-5-acetylamino-5-[2-(benzyloxycarbonyl-methyl-amino)-ethyl carbamoyl]-pentyl}-carbamic acid isopropyl ester 
• 1221593-55-0 {(S)-5-amino-5-[2-(benzyloxycarbonyl-methyl-amino)-ethylcarbamoyl]-pentyl}-carbamic acid tert-butyl ester 
• 1221593-54-9 {(S)-1-[2-(benzyloxycarbonyl-methyl-amino)-ethylcarbamoyl]-5-tert-butoxycarbonylamino-pentyl}-carbamic acid 9H-fluoren-9-ylmethyl ester 
• 1276121-44-8 [2-(benzyloxycarbonyl-methyl-amino)-ethyl]-dicarbamic acid tert-butyl ester 
• 533923-22-7 C₅₅H₆₅F₃N₆O₂₁ 
• 533923-27-2 C₄₆H₆₂N₆O₁₉ 

Relevant articles and documents

Pharmaceutical compositions with attenuated release of phenolic opioids

Pharmaceutical compositions and their methods of use are provided, where the pharmaceutical compositions comprise a phenolic opioid prodrug that provides enzymatically-controlled release of a phenolic opioid, and an enzyme inhibitor that interacts with th

COMPOSITIONS FOR REDUCING RISK OF ADVERSE EVENTS CAUSED BY DRUG-DRUG INTERACTIONS

The present disclosure provides a composition comprising a GABAA agonist and a GI enzyme inhibitor. The present disclosure also provides a composition comprising (a) a GI enzyme inhibitor and (b) a first drug that interacts with a second drug to produce an adverse effect when the second drug is co-ingested as a GI enzyme-cleavable prodrug with the first drug. Such an interaction can be additive or synergistic.

Compositions Comprising Enzyme-Cleavable Phenol-Modified Opioid Prodrugs and Inhibitors Thereof

Pharmaceutical compositions and their methods of use are provided, where the pharmaceutical compositions comprise a phenol-modified opioid prodrug that provides enzymatically-controlled release of a phenolic opioid, and an enzyme inhibitor that interacts with the enzyme(s) that mediates the enzymatically-controlled release of the phenolic opioid from the phenol-modified opioid prodrug so as to modify enzymatic cleavage of the phenol-modified opioid prodrug.